FDA has granted accelerated approval to the combination of Merck’s Keytruda (pembrolizumab) plus Esai’s Lenvima (lenvatinib) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high or mismatch repair deficient and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation.
Lillian L. Siu discovered her passion while perusing employment ads in the Journal of Clinical Oncology.
